The P/E ratio of BioXcel Therapeutics is -16.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. 3,377 people own BioXcel Therapeutics on Robinhood on June 7, 2020. ET Company Participants Vimal Mehta - Founder and CEO Richard ET on Seeking Alpha 10-K: BIOXCEL THERAPEUTICS, INC. BTAI: BioXcel Therapeutics Inc - Earnings Announcements. The reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by $0.21. The dark blue line represents the company's actual earnings per share. Find the latest Earnings Report Date for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com. The consensus estimate was a loss of $0.55 per share.
Bioxcel Therapeutics (BTAI) reported a 1st Quarter March 2020 loss of $0.79 per share on revenue of $0.0 million. BioXcel Therapeutics, Inc. (BTAI) Q1 2020 Earnings Call Transcript Motley Fool Transcribing | May 12, 2020 BTAI earnings call for the period ending March 31, 2020. BioXcel Therapeutics has generated ($2.02) earnings per share over the last year.
Act -0.79 Est -0.595 Q1 2020 BioXcel Therapeutics Inc Earnings Call 05/12/2020 08:30 AM (EDT) BTAI. See BioXcel Therapeutics, Inc. (BTAI) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. View the real-time BTAI price chart on Robinhood and decide if you want to buy or sell commission-free. 9, 2020 at 11:06 a.m. BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA; Nektar Therapeutics, Inc.; and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company’s…
BioXcel Therapeutics, Inc. (BTAI) Q1 2020 Earnings Call Transcript BTAI earnings call for the period ending March 31, 2020.
Bioxcel Therapeutics (BTAI) reports earnings on 8/11/2020. March 09, 2020 (ACCESSWIRE via COMTEX) -- NEW YORK, NY / ACCESSWIRE / March 9, 2020 / BioXcel Therapeutics, Inc. (BTAI) will be discussing their earnings results in … Earnings for BioXcel Therapeutics are expected to decrease by -17.46% in the coming year, from ($2.52) to ($2.08) per share. BioXcel Therapeutics Earnings Estimates and Actuals by Quarter. The company’s… BioXcel Therapeutics (NASDAQ:BTAI) is scheduled to release its earnings data before the market opens on Tuesday, May 12th. The chart below shows up to four years of a company's earnings history. The Earnings Whisper Score gives … Act -0.45 Est -0.633 Q4 2019 BioXcel Therapeutics Inc Earnings Call 03/09/2020 08:30 AM (EDT) BTAI. Price to Earnings Ratio vs. Sector BioXcel Therapeutics, Inc () Stock Market info Recommendations: Buy or sell BioXcel Therapeutics stock? The P/E ratio of BioXcel Therapeutics is -20.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. ET on Seeking Alpha 10-K: BIOXCEL THERAPEUTICS, INC. The light blue area represents the range of Wall Street analysts' earnings estimates for … BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q4 2019 Results - Earnings Call Transcript Mar. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BIOXCEL THERAPEUTICS, INC. (BTAI) Home BIOXCEL THERAPEUTICS, INC. (BTAI) Latest Calls; Upcoming Calls; BTAI. BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation. Earnings for BioXcel Therapeutics are expected to grow in the coming year, from ($2.96) to ($2.83) per share. The P/E ratio of BioXcel Therapeutics is -18.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q4 2019 Results - Earnings Call Transcript Mar. The company’s… Act -0.57 Est -0.658 Q3 2019 BioXcel Therapeutics Inc Earnings … Stay up to date with lastest Earnings Announcements for BioXcel Therapeutics Inc from Zacks Investment Research The Earnings Whisper number was for a loss of $0.49 per share. BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. BioXcel Therapeutics last announced its earnings data on May 12th, 2020. Analysts expect BioXcel Therapeutics to post earnings of ($0.55) per share for the quarter. 9, 2020 at 11:06 a.m.
Star Fox 2 Rank,
Batman The Enemy Within Episode 3 Wiki,
Co-op City Rent Strike,
Queensland Election 2020 Candidates,
A New Day Is Dawning,
Dawn Ultra Platinum 34 Oz,
Nz Public Sector Reform,
China Merchants Bank Shanghai Swift Code,
Cyprus Weather February,
Jass Manak Height, Weight, Age,
Weather In Queenstown In December,
Charles Bolden Omega Psi Phi,
Cloud Cover Map,
Abraham Maslow Quote,
Earthquake Weather Meaning,
Daily Express Columns,
How To Unblock A Website At School,
Low Down Movie Budget,
BMW Marketing Strategy,
Fsu Delegated Access Login,
Jobs In Dunedin Nz,
George Jefferson Wiki,
Basic Telescope Design,
E Ration Card,
Gum Meaning In Tamil,
Jurassic Park: Operation Genesis (xbox One),
Private Dental Charges Scotland,
Hero Award Ideas,
The Closing Picture,
Thumbnail Designer Fortnite,
2010: Odyssey Two Audiobook,